MoonLake Immunotherapeutics (MLTX) Times Interest Earned (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Times Interest Earned of -$30.45 for Q1 2026, up 76.41% year-over-year from -$17.26 in Q1 2025, and down 2.14% quarter-over-quarter from -$29.81 in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Times Interest Earned (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Times Interest Earned history runs 6 years deep, the most recent figure standing at -$30.45 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 76.41% year-over-year to -$30.45; the TTM figure through Mar 2026 stood at -$33.2 (up 77.42% YoY), while the FY2025 annual figure was -$33.78, down 488.57% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$30.45, down from -$29.81 in the prior quarter.
- The five-year high for Times Interest Earned was -$2.37 in Q2 2025, with the low at -$24265.3 in Q1 2022.
- The 5-year median for Times Interest Earned is -$86.9 (2023), against an average of -$1594.2.
- The sharpest annual moves came in 2022 and 2023: Times Interest Earned sank 5296.03% in 2022, then soared 98.63% in 2023.
- MoonLake Immunotherapeutics' Times Interest Earned stood at -$494.61 in 2022, then soared by 82.43% to -$86.9 in 2023, then slumped by 122.34% to -$193.21 in 2024, then soared by 84.57% to -$29.81 in 2025, then slipped by 2.14% to -$30.45 in 2026.
- Business Quant data shows MLTX's Times Interest Earned at -$30.45 in Q1 2026, -$29.81 in Q4 2025, and -$22.34 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | -3.62 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.62 |
| Mar 31, 2026 | -30.45 |
| Dec 31, 2025 | -29.81 |
| Sep 30, 2025 | -22.34 |
| Jun 30, 2025 | -2.37 |
| Mar 31, 2025 | -129.04 |
| Dec 31, 2024 | -193.21 |
| Sep 30, 2024 | -12.05 |
| Jun 30, 2024 | -147.67 |
| Mar 31, 2024 | -54.45 |
| Dec 31, 2023 | -86.90 |
| Sep 30, 2023 | -76.24 |
| Jun 30, 2023 | -62.08 |
| Mar 31, 2023 | -333.07 |
| Dec 31, 2022 | -494.61 |
| Sep 30, 2022 | -908.23 |
| Jun 30, 2022 | -254.06 |
| Mar 31, 2022 | -24,265.32 |
| Dec 31, 2021 | -9.17 |